Tivoxavir marboxil - Traws Pharma
Alternative Names: 27-5116; AV-5124 - Traws Pharma; Tivoxavir - Traws Pharma; TRX-100; viroksavir - Traws Pharma; Viroxavir marboxil - Traws PharmaLatest Information Update: 21 Oct 2024
Price :
$50 *
At a glance
- Originator Trawsfynydd Therapeutics
- Developer Traws Pharma
- Class Antivirals; Small molecules
- Mechanism of Action Endonuclease inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Influenza virus infections
Most Recent Events
- 08 Oct 2024 Traws Pharma plans a phase II trial in Influenza virus infections, in first half of 2025
- 08 Oct 2024 Pharmacodynamics data from a preclinical studies in Influenza virus infections released by Traws Pharma
- 08 Oct 2024 Pharmacokinetics and adverse events data from a phase I trial in Influenza virus infections (In volunteers) released by Traws Pharma